Cilostazol decreases total atrial conduction time in patients with peripheral artery disease.

Alizade, E; Sahin, M; Simsek, Z; Açar, G; Bulut, M; Güler, A; Avci, A; Kalkan, M E; Pala, S; Akçakoyun, M; Esen, A M

Alizade, E; Sahin, M; Simsek, Z; Açar, G; Bulut, M; Güler, A; Avci, A; Kalkan, M E; Pala, S; Akçakoyun, M; Esen, A M.

Affiliation

Alizade E; Kartal Kosuyolu Heart & Research Hospital, Cardiology Clinic, Kartal, Istanbul, Turkey.

Perfusion ; 29(3): 265-71, 2014 May.

Article in En | MEDLINE | ID: mdl-24280344

Subject(s)

Peripheral Arterial Disease/drug therapy; Peripheral Arterial Disease/physiopathology; Tetrazoles/administration & dosage; Vasodilator Agents/administration & dosage; Aged; Atrial Fibrillation/etiology; Atrial Fibrillation/physiopathology; Atrial Fibrillation/prevention & control; Cilostazol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peripheral Arterial Disease/complications

Key words

atrial fibrillation; cilostazol; peripheral artery disease; total atrial conduction time

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 Database: MEDLINE Main subject: Tetrazoles / Vasodilator Agents / Peripheral Arterial Disease Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Perfusion Year: 2014 Document type: Article

Fulltext

XML

PubMed Links

Search on Google